4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer.
Patients (186) with locally advanced or metastatic breast cancer were treated with the aromatase inhibitor 4-hydroxyandrostenedione given parenterally at 3 different doses. 21% of patients responded to treatment, 93% of objective responders whose oestrogen receptor (ER) status was known had ER positive tumours. The drug was well-tolerated particularly at a dose of 250 mg i.m. every fortnight. At this dose, only 4/96 (4%) patients had to discontinue treatment. We conclude that 4-hydroxyandrostenedione is a well-tolerated form of endocrine treatment for postmenopausal patients with breast cancer.
Coombes
R C
RC
Charing Cross Hospital, London, England.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000735:Androstenedione / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged
D000970:Antineoplastic Agents; D000735:Androstenedione; D004958:Estradiol; C014594:formestane